<DOC>
	<DOCNO>NCT00005868</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness docetaxel cisplatin treat patient untreated stage IIIA non-small cell lung cancer .</brief_summary>
	<brief_title>Docetaxel Cisplatin Treating Patients With Untreated Stage IIIA Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess therapeutic activity docetaxel cisplatin patient untreated stage IIIA non-small cell lung cancer . - Determine safety regimen patient . OUTLINE : This multicenter study . Patients receive docetaxel IV 1 hour day 1 cisplatin IV 30 minute day 1 2 . Treatment continue every 3 week 3 course absence disease progression unacceptable toxicity . Patients follow survival . PROJECTED ACCRUAL : A total 24-40 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IIIA nonsmall cell lung cancer ( NSCLC ) ( T13 , N2 , M0 ) Unresectable metastasis ipsilateral mediastinal and/or subcarinal lymph node Measurable disease Must least 20 mm one dimension conventional technique least 10 mm spiral CT scan No distant metastases No CNS involvement No pleural pericardial effusion PATIENT CHARACTERISTICS : Age : Over 18 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great upper limit normal ( ULN ) AST/ALT great 1.5 time ULN Alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 1.25 ULN Creatinine clearance least 60 mL/min Cardiovascular : No superior vena cava syndrome No uncontrolled congestive heart failure angina No myocardial infarction within past year No uncontrolled hypertension arrhythmia Other : Not pregnant nursing Fertile patient must use effective contraception No concurrent active infection require IV antibiotic therapy No prior malignancy past 5 year except carcinoma situ cervix adequately treat basal cell carcinoma , exclude melanoma , breast cancer , hypernephroma No concurrent illness medical condition contraindication corticosteroid therapy ( e.g. , active ulcer , unstable diabetes mellitus ) No motor sensory neurotoxicity grade 2 great No psychological , familial , sociological , geographical condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No prior chemotherapy NSCLC No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy Radiotherapy : No prior radiotherapy NSCLC No concurrent radiotherapy Surgery : No prior surgery NSCLC Other : At least 1 month since prior investigational agent No concurrent experimental medication</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
</DOC>